. Introduction {#s01}
==============

Sarcomas, consisted of soft tissue sarcomas (STSs) and bone sarcomas, are a heterogeneous group of mesenchymal malignancies that can develop at any age, comprising approximately 1% of all adult malignancies and 15% of pediatric malignancies^[@b1]^. Compared with other common cancer types, STSs can develop at almost any anatomical sites^[@b2]^, and are more prone to occur at childhood^[@b3]^. Although the etiology of STSs is still unclear, known risk factors include inherited syndromes, chemical and radiation exposures, viral infections and genetic mutations^[@b4],[@b5]^.

Due to their rarity, STSs are always outnumbered by carcinomas in many primary sites, therefore not reported in most researches categorizing cancers with the International Classification of Diseases^[@b6]^. In United States, it is estimated that 13,040 new cases and 5,150 deaths were caused by STSs in 2018, representing 0.75% of overall cancer incidence and 0.84% of overall cancer mortality^[@b7]^. In Europe, nearly 23,600 new STS cases rose annually and the crude incidence rate was 4.7 per 100,000^[@b6]^. In UK alone 3,300 new cases were diagnosed each year, with about 90 cases in children under 15 years oldd^[@b4]^. So far, most national and subnational epidemiological researches on the burden of STSs were carried out in developed countries^[@b3],[@b8]-[@b15]^.

Of all histological subtypes of STSs, gastrointestinal stromal tumor (GIST) was categorized as STS instead of digestive system cancer for the first time in the 2013 World Health Organization (WHO) Classification^[@b5],[@b16]^. Compared with other common cancer types in gastrointestinal tract, GIST starts in different types of cells and needs different types of treatment. Therefore, GIST was either treated as an entity equal to STSs and bone sarcomas^[@b6],[@b17]^, or reported separately from other STS subtypes^[@b18]-[@b20]^ in some researches. The crude incidence rate of GIST was 1.1--1.4 per 100,000 according to French and Spanish researches^[@b20],[@b21]^. Stomach is the most common site for GIST^[@b21]^ while there are some extremely rare tumors that arise outside the gastrointestinal tract but show the features of GIST. These tumors were therefore named extra-GIST^[@b22]^. Similar to the condition of overall STSs, few researches on the epidemiology of GIST and extra-GIST were carried out in developing countries.

With world's largest population, 23.7% of the global new cancer cases were estimated to occur in China in 2018^[@b23]^. However, little is known about the incidence of STS in this country. In order to have a comprehensive understanding on the cancer burden of STS in China, in this study we described the distribution of histological subtypes and primary sites of STS using updated data from 339 population-based cancer registries. Estimation of the incidence of STS in the whole Chinese population was made as well and was reported for GIST and STSs other than GIST (non-GIST STSs) separately. We also described the distribution of GIST and explored the proportion of extra-GIST.

. Materials and methods {#s02}
=======================

. Cancer registry data source {#s02.01}
-----------------------------

By 30th August 2017, 449 cancer registries from 31 provinces in China submitted cancer registry data for 2014 to National Central Cancer Registry of China (NCCRC). Local population data were provided along with the cancer data. After quality control based on the criteria of Chinese Guideline for Cancer Registration, data from 339 registries met the criteria and were finally included in this analysis. Among them, 129 were located in urban areas (covering a population of 144,061,915) and 210 were in rural areas (covering a population of 144,181,432). The overall population covered by these 339 cancer registries was 288,243,347 (146,203,891 men and 142,039,456 women), accounting for 21.07% of the national population that year.

All cancer cases were coded according to the International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) and the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10). Of all STS cases, the proportion of morphology verified cases (MV%) was 84.97%. More information on the national cancer registry program and data quality control procedure could be found elsewhere^[@b24],[@b25]^.

. Data extraction, classification and statistical analysis {#s02.02}
----------------------------------------------------------

STS cases in the 339 registries were retrieved and categorized into different histological groups according to their ICD-O-3 morphological codes as shown in [**Table 1**](#Table1){ref-type="table"} based on a previous study^[@b12]^. The primary site of a case was defined by the ICD-O-3 topographical code. Cases with topographical codes being C40-C41 were deleted to exclude sarcomas in bones, joints and articular cartilages.

###### 

Histological subtypes by ICD-O-3 morphological codes

  Histological group                                               ICD-O-3 codes
  ---------------------------------------------------------------- -------------------------------------------------
  Sarcoma NOS                                                      M8800--8806, M8000--8004 located in C48.0--49.9
  Gastrointestinal stromal tumor                                   M8936
  Leiomyosarcoma                                                   M8890--8896
  Endometrial stromal sarcoma                                      M8930--8935
  Liposarcoma                                                      M8850--8858
  Malignant fibrous histiocytoma                                   M8830
  Angiosarcoma                                                     M9120--9133, M9150 and M9170
  Rhabdomyosarcoma                                                 M8900--8920 and M8991
  Fibrosarcoma                                                     M8810--8815
  Nerve sheath tumor and malignant peripheral nerve sheath tumor   M9540--9571
  Dermatofibrosarcoma                                              M8832--8833
  Other specified soft tissue sarcoma                              
  　Carcinosarcoma, NOS                                            M8980
  　Synovial sarcoma                                               M9040--9043
  　Mixed tumor, malignant NOS                                     M8940
  　Primitive neuroectodermal tumor, NOS                           M9364 and M9473
  　Granular cell tumors and alveolar soft part sarcoma            M9580--9581
  　Paragangliomas and glomus tumors                               M8680--8711
  　Malignant mesenchymoma                                         M8990
  　Malignant myoepithelioma                                       M8982
  　Clear cell sarcoma                                             M9044
  　Kaposi sarcoma                                                 M9140
  　Rhabdoid tumor                                                 M8963
  　Extraskeletal osteosarcoma and chondrosarcoma                  M9180--9243
  　Myxosarcoma                                                    M8840
  　Malignant giant cell tumors                                    M9251

Crude incidence rates were calculated by area (urban/rural), sex (male/female) and age group (0, 1--4, 5 to 80 by 5 years, 85+) based on the retrieved cases. To estimate the number of new STS cases in the whole country, incidence rates stratified by area, sex and age group were multiplied by corresponding nationwide population in each stratum. National population data were obtained from Nation Bureau of Statistics. Chinese population in 2000 and World Segi's population were used for age-standardization.

The estimated nationwide incidence was reported for overall STSs, GIST, and non-GIST STSs separately. The distribution of histological subtypes was reported by sex and age group (0--19, 20--64, and over 65 years old) in order to reveal the sex and age predilection. Primary sites of all STS cases were classified into 14 groups and reported by sex.

. Results {#s03}
=========

. Incidence of soft tissue sarcoma {#s03.01}
----------------------------------

Approximately 39,900 new STS cases (19,200 men and 20,700 women) occurred nationwide China in 2014, as shown in [**Table 2**](#Table2){ref-type="table"}. The crude incidence rate was 2.91/100,000 (2.72/100,000 in men and 3.11/100,000 in women), while the age-standardized rate by Chinese population (ASRcn) and world population (ASRwld) were 2.21 and 2.13 per 100,000, respectively.

###### 

Estimated number of nationwide new cases of soft tissue sarcomas in China, 2014

                 Areas       Gender   Number of new cases   Incidence rate (1/100,000)   ASRcn (1/100,000)   ASRwld (1/100,000)
  -------------- ----------- -------- --------------------- ---------------------------- ------------------- --------------------
  Overall STS    All areas   Total    39,900                2.91                         2.21                2.13
  Male           19,200      2.72     2.10                  2.05                                             
  Female         20,700      3.11     2.32                  2.23                                             
  Urban areas    Total       26,600   3.55                  2.55                         2.47                
  Male           12,900      3.38     2.47                  2.40                                             
  Female         13,700      3.71     2.65                  2.54                                             
  Rural areas    Total       13,300   2.14                  1.74                         1.69                
                 Male        6,300    1.94                  1.61                         1.58                
                 Female      7,000    2.36                  1.89                         1.81                
  GIST           All areas   Total    5,700                 0.42                         0.29                0.29
  Male           3,200       0.45     0.32                  0.32                                             
  Female         2,500       0.38     0.26                  0.25                                             
  Urban areas    Total       3,900    0.52                  0.34                         0.34                
  Male           2,200       0.57     0.38                  0.38                                             
  Female         1,700       0.47     0.31                  0.30                                             
  Rural areas    Total       1,800    0.29                  0.22                         0.21                
  Male           1,000       0.30     0.24                  0.23                                             
  Female         800         0.28     0.20                  0.19                                             
  Non-GIST STS   All areas   Total    34,200                2.50                         1.92                1.85
  Male           16,000      2.27     1.78                  1.73                                             
  Female         18,200      2.73     2.06                  1.97                                             
  Urban areas    Total       22,700   3.03                  2.21                         2.13                
  Male           10,700      2.81     2.09                  2.02                                             
  Female         12,000      3.25     2.34                  2.25                                             
  Rural areas    Total       11,500   1.85                  1.52                         1.48                
  Male           5,300       1.64     1.37                  1.35                                             
  Female         6,200       2.09     1.69                  1.61                                             

There were 5,700 GIST cases (3,200 men and 2,500 women) nationwide in 2014, accounting for about 14.3% of the overall STSs. The crude incidence rate was 0.42/100,000 (0.45/100,000 in men and 0.38/100,000 in women). On the other hand, approximately 34,200 non-GIST cases (16,000 men and 18,200 women) were diagnosed, accounting for about 85.7% of the overall STSs. The crude incidence rate was 2.50/100,000 (2.27/100,000 in men and 2.73/100,000 in women). The incidence of overall STSs and non-GIST STSs were higher in women than in men in urban and rural areas, whereas the incidence of GIST was higher in men than in women in both areas.

As shown in [**Figure 1**](#Figure1){ref-type="fig"}, the age-specific incidence rates of overall STSs and non-GIST STSs were the lowest in children aged 5 to 9 years, increased dramatically after 35 years old and peaked at 75--79 years old in women and 80--84 years old in men for overall STSs, and 80-84 years old in both sexes for non-GIST STSs. As for GIST, the age-specific incidence rate was unstable due to the scarcity in individuals under 25 years old. The rate increased dramatically after 45 years old and peaked at 75--79 years old in women and 70--74 years old in men.

![Age-specific incidence for soft tissue sarcoma by sex in China, 2014. (A) All soft tissue sarcoma. (B) Gastrointestinal stromal tumor. (C) All soft tissue sarcoma excluding gastrointestinal stromal tumor.](cbm-16-3-565-1){#Figure1}

. Distribution of histological subtypes {#s03.02}
---------------------------------------

As shown in [**Table 3**](#Table3){ref-type="table"}, altogether 8,475 new STS cases (4,033 men and 4,442 women) were reported from the 339 cancer registries. The most common histological subtype was GIST (14.38%), followed by nerve sheath tumor and malignant peripheral nerve sheath tumor (MPNST) (12.48%), leiomyosarcoma (5.97%), liposarcoma (5.75%), and fibrosarcoma (5.73%).

###### 

Histological distribution of soft tissue sarcomas by sex and age in China, 2014

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Histological subtypes                                            Proportion (%)   Gender   Male/female ratio   0-19\        20-64\       65+\                 
                                                                                                                 years old\   years old\   years old\           
                                                                                                                 (%)          (%)          (%)                  
  ---------------------------------------------------------------- ---------------- -------- ------------------- ------------ ------------ ------------ ------- -------
  Sarcoma NOS                                                      28.65            2,428    1,198               1,230        1.0          3.50         54.08   42.42

  Gastrointestinal stromal tumor                                   14.38            1,219    669                 550          1.2          0.41         56.52   43.07

  Leiomyosarcoma                                                   5.97             506      95                  411          0.2          0.40         79.05   20.55

  Endometrial stromal sarcoma                                      4.46             378      30                  348          0.1          0.53         84.13   15.34

  Liposarcoma                                                      5.75             487      281                 206          1.4          2.26         66.74   31.00

  Malignant fibrous histiocytoma                                   5.12             434      269                 165          1.6          0.92         51.15   47.93

  Angiosarcoma                                                     4.59             389      212                 177          1.2          3.34         59.64   37.02

  Rhabdomyosarcoma                                                 1.43             121      64                  57           1.1          44.63        47.93   7.44

  Fibrosarcoma                                                     5.73             486      245                 241          1.0          2.67         72.22   25.10

  Nerve sheath tumor and malignant peripheral nerve sheath tumor   12.48            1,058    523                 535          1.0          2.74         80.72   16.54

  Dermatofibrosarcoma                                              2.28             193      114                 79           1.4          6.74         78.24   15.03

  Other specified soft tissue sarcoma                                                                                                                           

  　Carcinosarcoma, NOS                                            1.58             134      38                  96           0.4          0.00         61.19   38.81

  　Synovial sarcoma                                               1.18             100      51                  49           1.0          4.00         84.00   12.00

  　Mixed tumor, malignant NOS                                     0.86             73       31                  42           0.7          4.11         72.60   23.29

  　Primitive neuroectodermal tumor, NOS                           0.55             47       29                  18           1.6          14.89        76.60   8.51

  　Granular cell tumors and alveolar soft 　part sarcoma          1.16             98       15                  83           0.2          6.12         84.69   9.18

  　Paragangliomas and glomus tumors                               1.13             96       45                  51           0.9          3.13         79.17   17.71

  　Malignant mesenchymoma                                         0.88             75       37                  38           1.0          2.67         68.00   29.33

  　Malignant myoepithelioma                                       0.17             14       10                  4            2.5          0.00         64.29   35.71

  　Clear cell sarcoma                                             0.34             29       18                  11           1.6          6.90         72.41   20.69

  　Kaposi sarcoma                                                 0.59             50       29                  21           1.4          4.00         58.00   38.00

  　Rhabdoid tumor                                                 0.08             7        4                   3            1.3          28.57        57.14   14.29

  　Extraskeletal osteosarcoma and 　chondrosarcoma                0.26             22       13                  9            1.4          0.00         90.91   9.09

  　Myxosarcoma                                                    0.22             19       7                   12           0.6          0.00         57.89   42.11

  　Malignant giant cell tumors                                    0.14             12       6                   6            1.0          16.67        58.33   25.00

  Total                                                            100.00           8,475    4,033               4,442        0.9          3.12         64.65   32.24
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Overall male/female ratio was 0.9, indicating a female predilection. Highest ratios were found in malignant myoepithelioma, clear cell sarcoma, malignant fibrous histiocytoma and primitive neuroectodermal tumor NOS, whereas lowest ratios were found in endometrial stromal sarcoma, granular cell tumors and alveolar soft part sarcoma, leiomyosarcoma, carcinosarcoma NOS, and myxosarcoma.

Children and adolescents under 20 years old accounted for 3.12% of all STS cases, while adults aged 20-64 years and over 65 years accounted for 64.64% and 32.24%, respectively. In major histological subtypes, children and adolescents represented 44.63% of all rhabdomyosarcoma cases, whereas endometrial stromal sarcoma (84.13%) and nerve sheath tumor and MPNST (80.72%) occurred mainly in adults aged 20 to 64 years, and proportions of malignant fibrous histiocytoma (47.93%) and GIST (43.07%) were relatively high in elders above 65 years old.

. Distribution of primary sites {#s03.03}
-------------------------------

As shown in [**Table 4**](#Table4){ref-type="table"}, more than 22% of STSs were located in the connective, subcutaneous and other soft tissues, of which 574 were in lower limb and hip (lower extremities), 234 were in upper limb and shoulder (upper extremities). About one-fifth of STSs occurred in digestive organs, of which 952 were in stomach, 294 were in small intestine, and 153 were in liver. Retroperitoneum and peritoneum and eye, brain and other parts of the central nervous system both accounted for nearly 14% of all STSs.

###### 

Distribution of primary sites of soft tissue sarcomas by gender in China, 2014

  ICD-O-3 code    Primary sites                                                           Gender   Proportion (%)           
  --------------- ----------------------------------------------------------------------- -------- ---------------- ------- --------
  C00-C14         Lip, oral cavity and pharynx                                            82       57               139     1.64
  C15-C26         Digestive organs                                                        982      721              1,703   20.09
  　C16           Stomach                                                                 528      424              952     
  　C17           Small intestine                                                         164      130              294     
  　C22.0         Liver                                                                   100      53               153     
  C30-C39         Respiratory system and intrathoracic organs                             214      112              326     3.85
  C44             Skin                                                                    203      146              349     4.12
  C47             Peripheral nerve and autonomic nerve system                             44       48               92      1.09
  C48             Retroperitoneum and peritoneum                                          567      660              1,227   14.48
  C49             Connective, subcutaneous and other soft tissues                         1,061    855              1,916   22.61
  　C49.0         Head, face and neck                                                     112      84               196     
  　C49.1         Upper limb and shoulder                                                 142      92               234     
  　C49.2         Lower limb and hip                                                      325      249              574     
  　C49.3         Thorax                                                                  76       66               142     
  　C49.4         Abdomen                                                                 88       105              193     
  　C49.5         Pelvis                                                                  81       80               161     
  　C49.6         Trunk                                                                   85       47               132     
  　C49.8         Overlapping lesion                                                      4        4                8       
  　C49.9         NOS                                                                     148      128              276     
  C50             Breast                                                                  2        87               89      1.05
  C51-C57         Female genital organs                                                   0        924              924     10.90
  C60-C63         Male genital organs                                                     51       0                51      0.60
  C64-C68         Urinary tract                                                           71       43               114     1.35
  C69-C72         Eye, brain and other parts of the central nervous system                550      582              1,132   13.36
  　C71           Brain                                                                   117      146              263     
  　C72           Spinal cord, cranial nerves and other parts of central nervous system   396      362              758     
  C73-C75         Thyroid and other endocrine glands                                      39       46               85      1.00
  C76, C77, C80   Lymph nodes and other sites                                             167      161              328     3.87
  Total                                                                                   4,033    4,442            8,475   100.00

As shown in [**Table 5**](#Table5){ref-type="table"}, of all GIST cases, 98.6% arose in digestive organs. Stomach was the most common site (67.51%), followed by small intestine (20.92%), other digestive organs (4.59%) and rectum (3.12%). Extra-GIST was found in retroperitoneum and peritoneum, bronchus and lung, soft tissues, thyroid gland, and other unknown sites, representing 1.4% of all GIST cases.

###### 

Distribution of primary sites of gastrointestinal stromal tumor by sex in China, 2014

  ICD-O-3 code   Primary sites                                     Gender   Proportion (%)           
  -------------- ------------------------------------------------- -------- ---------------- ------- --------
  C15            Esophagus                                         6        3                9       0.74
  C16            Stomach                                           444      379              823     67.51
  C17            Small intestine                                   141      114              255     20.92
  C18            Colon                                             10       9                19      1.56
  C20            Rectum                                            26       12               38      3.12
  C21            Anus and anal canal                               1        0                1       0.08
  C25            Pancreas                                          1        0                1       0.08
  C26            Other digestive organs                            29       27               56      4.59
  C34            Bronchus and lung                                 0        1                1       0.08
  C48            Retroperitoneum and peritoneum                    5        1                6       0.49
  C49            Connective, subcutaneous and other soft tissues   2        0                2       0.16
  C73            Thyroid gland                                     1        0                1       0.08
  C76            Other and ill-defined sites                       3        3                6       0.49
  C80            Unknown primary site                              0        1                1       0.08
  Total                                                            669      550              1,219   100.00

. Discussion {#s04}
============

In this study, using population-based cancer registry data, we found that nearly 39,900 new STS cases (5,700 GIST and 34,200 non-GIST) were diagnosed nationwide in China in 2014, representing 1.05% (0.90% in male, 1.23% in female) of all cancer incidence^[@b24]^, larger than the proportion (0.75%) in United States^[@b7]^. Crude incidence rates of STSs and GIST were 2.91 and 0.42 per 100,000 respectively, lower than the corresponding rates in western countries (4.7 and 0.78 per 100,000)^[@b6],[@b19]^.

Incidence of STS in China generally increased with age. The rate in Austria showed similar trend but peaked and dropped at younger ages^[@b14]^. Unlike carcinomas, STSs comprise a large proportion of pediatric malignancies and are an important cause of death in adolescents and young adults^[@b3],[@b4]^. In our study, 3.1% of all STSs occurred in individuals aged 0 to 19 years, whereas in United States and Japan, corresponding proportions were 5.6% and 6.7%, respectively^[@b3],[@b12]^. Rhabdomyosarcoma was the only entity with a median age \< 20 years in United States. It was also the most common subtype in people under 20 years old in these three studies.

Unlike most carcinomas, to which men are prone to develop, contradictions remained as for the major gender of STS patients. In Europe, there were more female patients^[@b6],[@b14]^, while in Korea and Taiwan China, results showed the opposite^[@b13],[@b26]^. Similar to these Asian results, men outnumbered women in most primary sites and histological subtypes in our study. However, there were more female patients due to the numerous cases in breast and female genital organs, and subtypes like leiomyosarcoma, which occurs mainly in genital organs, bladder and uterus.

GIST was the most common histological subtype in Chinese population, as was found in Europe^[@b15]^. In France, 16.7% of the identified sarcoma cases were GIST. French distribution of GIST was similar to our study, with 61% and 27% arose in stomach and small intestine, respectively. The proportion of extra-GIST nevertheless was greater because 5% of GIST arose in peritoneum. This extravagant percentage can be partly explained by the small sample size^[@b21]^. In contrast to our and American results^[@b19]^, GIST showed a female predilection in France. In United States, there were relatively less GIST in stomach (55.3%) and more in small intestine (28.7%), while the proportion of extra-GIST was 3.0%, also larger than our result^[@b19]^.

Kaposi sarcoma, accounting for less than 0.6% of all STSs, was only a minor subtype in China and even less common (0.2%) in Japan^[@b12]^, whereas it had very high incidence in African countries^[@b27]^. Kaposi sarcoma is also the most common subtype (31.7%) in United States^[@b3]^. This could be explained by the relatively low prevalence of HIV in East Asia because Kaposi sarcoma is strongly related with immune suppression^[@b28]^.

Other than Kaposi sarcoma, common subtypes in United States were fibrohistiocytic tumors (30.4%) and leiomyosarcoma (27.4%)^[@b3]^. Even after the inclusion of GIST into the leiomyosarcoma category, corresponding proportions in our study, which were 5.12% and 20.35% respectively, were still smaller than these results. In Japan, leiomyosarcoma (28.1%) was the most prevalent subtype, followed by liposarcoma (9.6%), and malignant fibrous histiocytoma (9.0%)^[@b12]^. In contrast, nerve sheath tumor and MPNST is far more prevalent in China, representing more than 12% of all STSs in our study, compared with 3.5% in Japan and 4.6% in United States.

In terms of primary sites, according to American Cancer Society, STSs can develop in soft tissues, internal organs as well as retroperitoneum^[@b29]^. However, the WHO classification did not include internal organs as primary sites for STSs and listed only the extremities, trunk wall, and retroperitoneum^[@b5]^. Therefore, STSs were recognized as an entity with a variety of primary sites in some studies^[@b10]-[@b12],[@b14]^, while in others, STSs were more confined and sarcomas in internal organs were categorized as visceral sarcoma separately^[@b8],[@b15]^.

In this study, we used the classification of American Cancer Society, and found that connective, subcutaneous and other soft tissues was the most common site. Delving into more specific topographic categories, lower extremity was the most common subsite, and the number of cases in lower extremity was 2--3 times of that in upper extremity. Results in Korea^[@b13]^, Japan^[@b12],[@b30]^ and Europe^[@b15]^ further proved ours. Digestive organs, which was recognized as visceral sarcomas in some studies, were the second most common site for STSs, of which the majority was GIST. We found 17 extremely rare extra-GIST cases based on this large population-based study. This will provide valuable epidemiological evidence for further researches.

STSs have more than 70 histological subtypes^[@b15]^. Together with the various primary sites, they make up a large number of combinations that vary tremendously in terms of survival and clinical treatment, which means that same histological subtype in different sites may need completely different therapies^[@b6],[@b31]^. The rarity of STSs and the even smaller number of cases in each combination further add to the difficulty faced by researchers and physicians. Although the national survival of STSs in China is still unknown, overall five-year survival rate of STSs in developed countries ranged from 55% to 78%^[@b4],[@b8],[@b30]^, indicating a relatively optimistic prognosis. Nevertheless, survival may vary tremendously (48.0%-99.5%) between different subtypes^[@b30]^, and would worsen along with ageing^[@b3]^. This, together with its scarcity, emphasize that more attention should be paid to this less noticed disease and its patients.

Some limitations of this study should be noticed. First, probable methodology bias remains. We retrieved data based on ICD-O-3 morphological codes in this study because STSs can arise in almost every part in the human body, making topographical codes less useful than in the analysis of carcinomas. Nevertheless, according to a European study, nearly 42% of the first histological diagnoses of STSs were inaccurate. This heterogeneity and discrepancy can lead to misreport on subtype incidence^[@b4],[@b32]^ and consequently bias the results on the epidemiology of STSs. Second, proportion of sarcoma NOS was too high compared with Japanese results^[@b12]^, and MV% was lower than that in Europe^[@b6]^, indicating a necessity to strengthen the pathological diagnosis especially in rural China.

. Conclusions {#s05}
=============

This study is the first in China mainland to report the nationwide incidence of STS as well as the distribution of histological subtypes and primary sites. As a group of rare malignancies in China, STSs are more common in children than carcinomas. With numerous histological subtypes and primary sites, tremendous variations remain in STSs, which impose an arduous challenge to both medical researchers and doctors and emphasize more attention.
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